Roughly 80% of women experience hot flashes during the menopause transition, and 40 to 60% have moderate-to-severe vasomotor symptoms that disrupt daily life, according to Menopause Society data. Yet many women seeking relief encounter conflicting messages. Older fears tied to the FDA’s black-box warning now sit alongside news of its reversal, while new drug names such as Veozah and Lynkuet crowd the conversation.
This guide maps the full landscape of menopause medication by mechanism, candidacy, and comorbidity rather than by brand, covering systemic hormone therapy, neurokinin receptor antagonists, local vaginal estrogen, and older non-hormonal agents. It is meant to help readers prepare for a consult, not to rank a “best” drug.
The 2025 and 2026 Regulatory Shift: What Changed
On November 10, 2025, the FDA announced it would remove the black-box warning from menopausal hormone therapy (MHT), with finalized labeling changes for six MHT products completed on February 12, 2026. The boxed warnings for cardiovascular disease, breast cancer, and probable dementia were removed, though the endometrial cancer warning remains on estrogen-only products for women with a uterus. The removal of the black box lowers a barrier to appropriate care and reflects evolving evidence, though it does not mean MHT is right for every woman.
FDA Commissioner Dr. Marty Makary called the original warning “one of the greatest mistakes in modern medicine” and said HRT may improve population health outcomes more than any intervention except antibiotics or vaccines.
Other changes followed:
- Veozah (fezolinetant) received a 2025 warning about a rare but serious risk of liver injury. This affects monitoring and does not automatically disqualify patients.
- Elinzanetant (Lynkuet), approved in fall 2025, is a second-generation option that also targets a receptor tied to sleep.
- ACOG Clinical Practice Guideline No. 13, published October 15, 2026, is the first full update since 2014, tying these developments into a current standard of care.
How Clinicians Sequence Menopause Medication
Choosing a therapy means matching mechanism to symptom profile, time since menopause onset, and comorbidities. Clinicians generally consider four categories:
- Systemic hormone therapy
- Non-hormonal neurokinin receptor antagonists
- Local or vaginal estrogen for genitourinary symptoms
- Older non-hormonal agents (gabapentin, SSRIs/SNRIs)
ACOG’s 2026 guidance gives systemic hormone therapy a “strong” recommendation for vasomotor symptoms and related sleep disturbance in women without contraindications, making it a frequent first-line option. Candidacy screening comes before mechanism selection, and it covers age, timing, personal and family history, and cardiovascular and cancer risk.
Systemic Hormone Therapy (MHT/HRT)
Systemic therapy replaces declining estrogen to address hot flashes, sleep, and related changes. Women with a uterus take estrogen plus a progestogen, which protects the endometrium. Women without a uterus take estrogen alone. ACOG also endorses conjugated estrogen plus bazedoxifene as an alternative to estrogen-progestogen therapy for appropriate candidates. The best benefit-risk balance comes when therapy starts before age 60 or within 10 years of natural menopause onset.
The End of “Lowest Dose, Shortest Time”
ACOG’s 2026 guideline formally drops the blanket rule of minimal dose and duration, making duration an individualized decision that the patient and clinician revisit over time rather than stopping at a fixed cutoff.
Who Is (and Isn’t) a Candidate
General candidates are women with moderate-to-severe vasomotor symptoms and no major contraindications. Some factors change the conversation:
- Cardiovascular risk factors
- Migraine with aura
- Personal history of breast or endometrial cancer
These factors may point toward non-hormonal options or specific formulations, such as transdermal estrogen for certain cardiovascular or clotting concerns. ACOG notes that evidence remains insufficient to recommend hormone therapy specifically for depressive symptoms.
Non-Hormonal Neurokinin (NK3) Receptor Antagonists
These drugs block neurokinin B signaling in the hypothalamus, acting on the KNDy-neuron pathway that drives hot flashes and helping restore normal temperature regulation.
- Fezolinetant (Veozah) was approved May 12, 2023, as the first drug in this class, serving women who cannot or prefer not to use hormones. Because of its 2025 liver-injury warning, patients need baseline and periodic liver function testing, which is especially important for women with existing liver conditions.
- Elinzanetant (Lynkuet) blocks an additional receptor that may help with nighttime waking.
ACOG’s 2026 guideline endorses both drugs as evidence-based non-hormonal options.
Local and Vaginal Estrogen for Genitourinary Symptoms
Genitourinary syndrome of menopause (GSM) includes vaginal dryness, irritation, and urinary symptoms. It affects 40 to 55% of postmenopausal women, yet only about 7% receive prescription treatment. Low-dose vaginal estrogen has minimal systemic absorption, so many women who cannot use systemic therapy can still use it, including many breast cancer survivors with oncology coordination. Unlike some vasomotor symptoms, GSM does not resolve on its own.
Older Non-Hormonal Options: Gabapentin and SSRIs/SNRIs
ACOG suggests gabapentin when other non-hormonal options fail or are not tolerated. SSRIs and SNRIs, including venlafaxine-class agents, can help women with concurrent depression or anxiety. Few head-to-head trials compare fezolinetant to these agents, so clinicians often choose based on comorbidity and side-effect tolerance.
Choosing by Comorbidity: A Clinical Decision Framework
- Depression/anxiety: SSRIs/SNRIs may address mood and vasomotor symptoms together.
- Migraine with aura: The route of estrogen matters, and transdermal may be preferred. Sometimes non-hormonal options are a better fit.
- Cardiovascular risk: The label change reframes risk, but individualized assessment is still needed.
- Breast cancer history: Vaginal estrogen may remain an option for GSM with oncology input. Non-hormonal agents become the primary path for vasomotor symptoms.
- Liver health: The Veozah labeling matters for women with existing liver conditions.
Emerging and Off-Label Areas: Testosterone and Compounded Bioidentical Hormones
No testosterone product is FDA-approved for women in the U.S. Use for low libido (HSDD) remains off-label, typically with male-formulated or compounded products. The FDA’s September 2026 public workshop on standardizing access signals that this area is still evolving.
ACOG, The Menopause Society, and the Endocrine Society continue to recommend FDA-approved menopausal hormone therapies over compounded bioidentical hormone therapy. They cite a 2020 NASEM report that documented dosing variability, contamination risk, and a lack of adverse-event reporting. FDA-approved bioidentical-type options already exist, including estradiol patches, gels, and micronized progesterone.
Menopause, Metabolic Change, and the Role of GLP-1 Medications
Hormonal shifts during menopause often coincide with visceral weight gain and metabolic change, a related concern but separate from hot flashes and GSM. GLP-1 medications are increasingly discussed as an adjunct tool here, though they are not a treatment for menopause symptoms themselves. In general terms, these medications act on appetite and metabolic signaling pathways.
Red Mountain offers brand-name GLP-1 medications, compounded GLP-1 medications, and its own legacy RM3 program. Each is a tool within a broader metabolic strategy that includes nutrition support, muscle preservation, and ongoing monitoring.
The Treatment Gap: Why So Many Women Remain Untreated
A 2025 Mayo Clinic study of nearly 5,000 women found that more than 80% did not seek care, even though over one-third reported moderate to very severe symptoms. A 2025 survey found that 69% of U.S. women aged 40 to 65 were not treating their symptoms, and 10% would actively avoid hormone therapy.
Several factors likely drive this gap:
- Lingering fear from the black-box era
- Being told symptoms are “normal”
- Clinicians who are unfamiliar with updated guidance
- Fragmented information online
This reflects a failure of the care system, not a lack of effective treatment.
Why Individualized, Physician-Supervised Care Matters Now
With this many mechanisms, comorbidities, and regulatory changes, the right decision depends on an individualized evaluation. Red Mountain’s physician-supervised, in-person model draws on more than 30 years of clinical experience. Its clinicians weigh hormone therapy, non-hormonal options, and local treatments against each patient’s full history, consistent with ACOG’s shared decision-making framework. Medication is one tool; ongoing monitoring, symptom reassessment, and adjustment over time provide the structure around it.
Conclusion: Moving From Confusion to a Clear Next Step
The map of menopause medication has been redrawn. The black-box warning is gone, Veozah carries new liver-injury labeling, elinzanetant has arrived, and ACOG’s October 2026 guideline sets a new standard of care. No single drug is “the answer.” The right choice depends on symptom type, timing, and health history. This guide is best used as preparation for a clinical conversation, not a substitute for one.
Next Step: Discussing Options With a Clinician
For women who recognize their own symptoms in this guide, a consult is usually the natural next step. At Red Mountain, the evaluation applies this full landscape to each woman’s history, labs, and goals. Understanding the options is the first step, and the consult is where individualized decisions are made.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
